WeChat Mini Program
Old Version Features
Research Interests

Papers共 657 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
HER2DX ERBB2 Mrna Score in First-Line Advanced HER2-positive Breast Cancer Treated with Chemotherapy, Trastuzumab, and Pertuzumab
Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero,Elia Seguí,Esther Carcelero,Pablo Tolosa,Jesús Soberino, Manuel Alva,Tomás Pascual,Laura Lema,Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey,Luis Manso, Angela Aguirre,Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo,Patricia Galván,Esther Sanfeliu,Guillermo Villacampa, Wesley Buckingham,Mercedes Marín-Aguilera,Laia Paré,Patricia Villagrasa, Charles M. Perou,Julia Maues,Fara Brasó-Maristany,Eva Ciruelos,Aleix Prat
npj Breast Cancerno. 1 (2025): 1-7
Cited0Views0WOSNATUREBibtex
0
0
Selective Tubulin-Binding Drugs Induce Pericyte Phenotype Switching and Anti-Cancer Immunity
Bo He, Kira H Wood,Zhi-Jie Li, Judith A Ermer, Ji Li, Edward R Bastow, Suraj Sakaram,Phillip K Darcy, Lisa J Spalding, Cameron T Redfern,Jordi Canes,Mafalda Oliveira,Aleix Prat, Javier Cortes,Erik W Thompson,Bruce A Littlefield,Andrew Redfern,Ruth Ganss
EMBO molecular medicineno. 5 (2025): 1071-1100
Cited0Views0WOSBibtex
0
0
Unlocking the Potential of Engineered Immune Cell Therapy for Solid Tumors
Víctor Albarrán-Fernández,Laura Angelats,Julio Delgado,Alena Gros, Álvaro Urbano-Ispizua,Sònia Guedan,Aleix Prat
Nature communicationsno. 1 (2025): 1144-1144
Cited0Views0WOSNATUREBibtex
0
0
Load More
Author Statistics

#Papers: 657

#Citation: 23061

H-Index: 76

G-Index: 146

Sociability: 8

Diversity: 3

Activity: 422

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn